Treatment of leprosy

British Medical Journal

Volumn 328, Issue 7454, 2004, Pages 1447-1448

  Lockwood, Diana N J ^a   Kumar, Bhushan ^b  

^a HOSPITAL FOR TROPICAL DISEASES   (United Kingdom)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CLOFAZIMINE; DAPSONE; MINOCYCLINE; OFLOXACIN; PREDNISOLONE; RIFAMPICIN; STEROID;

DISEASE COURSE; EDITORIAL; FOLLOW UP; HUMAN; IMMUNE RESPONSE; LEPROSY; NERVE INJURY; PERIPHERAL NERVE INJURY; PHYSIOTHERAPY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZATION; REDUCTION; RELAPSE; SKIN DEFECT; WORLD HEALTH ORGANIZATION;

EID: 3042606267     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.328.7454.1447     Document Type: Editorial

References (12)

1. World Health Organization. Chemotherapy of leprosy for control programmes. Geneva: WHO, 1982. (Technical Report Series, 675.)
2. World Health Organization. Report on third meeting of the WHO technical advisory group on elimination of leprosy. Geneva: WHO, 2002. WHO/CDS/ CPE/CEE/2002.29
3. WHO Expert Committee on leprosy. Seventh report. Geneva, World Health Organization, 1998. (Technical Report Series, 874.)
4. Lockwood DN. Leprosy. Clin Evid 2002;8:709-20.
5. Girdhar BK, Girdhar A, Kumar A. Relapses in multibacillary leprosy patients: effect of length of therapy. Lepr Rev 2000;71:144-15.
6. Ji B. Does there exist a subgroup of MB patients at greater risk of relapse after MDT? Lepr Rev 2001;72:3-7.
7. Lockwood DN. Rifampicin, ofloxacin and minocycline (ROM) for single lesions in leprosy. What is the evidence? Lepr Rev 1997;6:299-300.
8. Villahermosa L, Fajardo T, Abalos R, Cellona R, Balagon M, dela Cruz E, et al. Parallel assessment of 24 monthly doses of rifampicin, ofloxacin and minocycline (ROM) versus 2 year WHO multidrug therapy (MDT) in multibacillary leprosy. Am J Trop Med Hyg (in press).
9. Croft RP, Nicholls PG, Steyerberg EW, Richardus JH, Withington SG, Smith WC. A clinical prediction rule for nerve function impairment in leprosy patients - revisited after 5 years of follow-up. Lepr Rev 2003;74: 35-41.
10. Britton WJ. The management of leprosy reversal reactions. Lepr Rev 1998;69:225-34.
11. Smith WCS, Anderson AM, Withington SG, van Brakel WH, Croft RP, Nicholls PG, et al. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1). BMJ 2004;328:1459-62.
12. Lockwood DN, Bryceson ADB. The return of thalidomide: new uses and renewed concerns - a reply. Lepr Rev 2003;74:290-3.